Analysis Tools
mortality/aging
|
• at 15 weeks, 3 of 8 mice treated with 28 mg/kg kainate die unlike similarly treated wild-type mice
|
|
• at 16 months of age, 20% to 30% of mice survive whereas almost all wild-type mice are alive
|
nervous system
|
• at 15 weeks, kainate-treated mice exhibit myoclonic epilepsy and serious brain damage unlike wild-type mice that exhibit mild neuronal damage
|
|
• at 15 weeks, kainate-treated mice exhibit myoclonic epilepsy and serious brain damage unlike wild-type mice that exhibit mild neuronal damage
|
|
• mice exhibit severe neuronal cell damage with heavy glial cell activation unlike in wild-type mice
|
|
• mice exhibit severe neuronal cell damage with heavy glial cell activation unlike in wild-type mice
|
|
• at 30 weeks
|
behavior/neurological
|
• at 3 months of age, mice exhibit crouching, bending back and abnormal jumping that often result in self-injury unlike wild-type mice
|
|
• at 15 weeks, kainate-treated mice exhibit myoclonic epilepsy and serious brain damage unlike wild-type mice that exhibit mild neuronal damage
|
homeostasis/metabolism
|
• at 15 weeks, kainate-treated mice exhibit myoclonic epilepsy and serious brain damage unlike wild-type mice that exhibit mild neuronal damage
|
|
• at 15 weeks, 3 of 8 mice treated with 28 mg/kg kainate die unlike similarly treated wild-type mice
|
muscle
|
• at 15 weeks, kainate-treated mice exhibit myoclonic epilepsy and serious brain damage unlike wild-type mice that exhibit mild neuronal damage
|
cellular
|
• at 15 weeks, kainate-treated mice exhibit myoclonic epilepsy and serious brain damage unlike wild-type mice that exhibit mild neuronal damage
|
